Overview

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Subjects With Dry Eye.

Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
Phase:
Phase 3
Details
Lead Sponsor:
BRIM Biotechnology Inc.
Treatments:
Ophthalmic Solutions